High incidence of appropriate implantable cardioverter-defibrillator therapy in patients with syncope of unknown etiology and inducible ventricular arrhythmias
MS Link,
XF Costeas,
JL Griffith,
CD Colburn,
NA Estes 3rd,
and
PJ Wang
Division of Cardiology, New England Medical Center, Boston, Massachusetts 02111, USA. Mark.Link@e.s.NEMC.ORG
OBJECTIVES: This study evaluates the hypothesis that in patients with syncope of unknown origin, inducible ventricular arrhythmias are specific arrhythmias and therefore should be appropriately treated. BACKGROUND: Although syncope is a common clinical entity, the evaluation and treatment of patients with syncope without a clear etiology are not well defined. Many patients with syncope of undetermined origin undergo invasive electrophysiologic evaluation. Abnormalities of the sinus node, prolongation of conduction times or inducible arrhythmias found at these evaluations are usually assumed to be the cause of syncope and are therefore treated. However, whether tachyarrhythmias are truly the cause of syncope, and whether treatment of these tachyarrhythmias can prevent recurrent syncope and arrhythmic death, is unknown. METHODS: This study included 50 consecutive patients with syncope of undetermined origin, ventricular tachyarrhythmias at electrophysiologic evaluation and treatment with an implantable cardioverter-defibrillator. RESULTS: Ventricular stimulation led to sustained monomorphic ventricular tachycardia in 36 patients, nonsustained ventricular tachycardia in 5 and ventricular fibrillation in 9. Over a 23 +/- 15-month (mean +/- SD) follow-up period, 18 patients received appropriate implantable cardioverter-defibrillator shock. Actuarial probability of appropriate therapy was 22% at 1 year and 50% at 3 years. Recurrent syncope was seen in five patients, three of whom had appropriate defibrillatory detections at the time of syncope. Four patients died (sudden death in one, congestive heart failure in two). CONCLUSIONS: In patients with syncope of undetermined origin and inducible ventricular tachyarrhythmias, appropriate implantable cardioverter-defibrillator therapy is common at follow-up. Sudden cardiac death is uncommon. This low incidence of sudden cardiac death and high incidence of appropriate defibrillator therapy support the current practice of using implantable cardioverter-defibrillators in patients with syncope of unknown origin and inducible ventricular arrhythmias.
This article has been cited by other articles:

|
 |

|
 |
 
M. Brignole, J.-J. Blanc, R. Sutton, and A. Moya
CHAPTER 26 Syncope
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Olshansky, J. E. Poole, G. Johnson, J. Anderson, A. S. Hellkamp, D. Packer, D. B. Mark, K. L. Lee, G. H. Bardy, and for the SCD-HeFT Investigators
Syncope Predicts the Outcome of Cardiomyopathy Patients: Analysis of the SCD-HeFT Study
J. Am. Coll. Cardiol.,
April 1, 2008;
51(13):
1277 - 1282.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Lombardi, E. Calosso, G. Mascioli, E. Marangoni, A. Donato, S. Rossi, M. Pala, F. Foti, and M. Lunati
Utility of implantable loop recorder (Reveal PlusŪ) in the diagnosis of unexplained syncope
Europace,
January 1, 2005;
7(1):
19 - 24.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Guidelines on Management (diagnosis and treatment) of syncope - update 2004: The Task Force on Syncope, European Society of Cardiology
Europace,
January 1, 2004;
6(6):
467 - 537.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. D. Krahn, G. J. Klein, R. Yee, J. S. Hoch, and A. C. Skanes
Cost implications of testing strategy in patients with syncope: Randomized assessment of syncope trial
J. Am. Coll. Cardiol.,
August 6, 2003;
42(3):
495 - 501.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Pezawas, G. Stix, J. Kastner, M. Wolzt, C. Mayer, D. Moertl, and H. Schmidinger
Unexplained syncope in patients with structural heart disease and no documented ventricular arrhythmias: value of electrophysiologically guided implantablecardioverter defibrillator therapy
Europace,
January 1, 2003;
5(3):
305 - 312.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Menozzi, M. Brignole, R. Garcia-Civera, A. Moya, G. Botto, L. Tercedor, R. Migliorini, X. Navarro, and on behalf of the International Study on Syncope of
Mechanism of Syncope in Patients With Heart Disease and Negative Electrophysiologic Test
Circulation,
June 11, 2002;
105(23):
2741 - 2745.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Garcia-Moran, L. Mont, A. Cuesta, M. Matas, and J. Brugada
Low recurrence of syncope in patients with inducible sustained ventricular tachyarrhythmias treated with an implantable cardioverter-defibrillator
Eur. Heart J.,
June 1, 2002;
23(11):
901 - 907.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Mittal, S. C. Hao, S. Iwai, K. M. Stein, S. M. Markowitz, D. J. Slotwiner, and B. B. Lerman
Significance of inducible ventricular fibrillation in patients with coronary artery disease and unexplained syncope
J. Am. Coll. Cardiol.,
August 1, 2001;
38(2):
371 - 376.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Task Force on Syncope, European Society of Cardiol, M Brignole, P Alboni, D Benditt, L Bergfeldt, J.J Blanc, P.E Bloch Thomsen, J.G van Dijk, A Fitzpatrick, S Hohnloser, et al.
Guidelines on management (diagnosis and treatment) of syncope
Eur. Heart J.,
August 1, 2001;
22(15):
1256 - 1306.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Josephson, D. J. Callans, and A. E. Buxton
The Role of the Implantable Cardioverter-Defibrillator for Prevention of Sudden Cardiac Death
Ann Intern Med,
December 5, 2000;
133(11):
901 - 910.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. P. Andrews, R. I. Fogel, G. Pelargonio, J. J. Evans, and E. N. Prystowsky
Implantable defibrillator event rates in patients with unexplained syncope and inducible sustained ventricular tachyarrhythmias: A comparison with patients known to have sustained ventricular tachycardia
J. Am. Coll. Cardiol.,
December 1, 1999;
34(7):
2023 - 2030.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Mittal, S. Iwai, K. M. Stein, S. M. Markowitz, D. J. Slotwiner, and B. B. Lerman
Long-term outcome of patients with unexplained syncope treated with an electrophysiologic-guided approach in the implantable cardioverter-defibrillator era
J. Am. Coll. Cardiol.,
October 1, 1999;
34(4):
1082 - 1089.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Mont, M. Valentino, A. Sambola, M. Matas, L. Aguinaga, and J. Brugada
Arrhythmia recurrence in patients with a healed myocardial infarction who received an implantable defibrillator: analysis according to the clinical presentation
J. Am. Coll. Cardiol.,
August 1, 1999;
34(2):
351 - 357.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. P. Knight, R. Goyal, F. Pelosi, M. Flemming, L. Horwood, F. Morady, and S. A. Strickberger
Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator
J. Am. Coll. Cardiol.,
June 1, 1999;
33(7):
1964 - 1970.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. D. Krahn, G. J. Klein, R. Yee, T. Takle-Newhouse, and C. Norris
Use of an Extended Monitoring Strategy in Patients With Problematic Syncope
Circulation,
January 26, 1999;
99(3):
406 - 410.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|